Utilization of real-world data in assessing treatment effectiveness for diffuse large B-cell lymphoma.

ABSTRACT: Direct comparisons of the effectiveness of the numerous novel therapies in the diffuse large B-cell lymphoma (DLBCL) treatment landscape in a range of head-to-head randomized phase 3 trials would be time-consuming and costly. Comparative effectiveness studies using real-world data (RWD) represent a complementary approach. Recently, several studies of relapsed/refractory (R/R) DLBCL have used RWD to create observational cohorts to compare patient outcomes with cohorts derived from single-arm phase 2 trials. Using propensity score methods to balance clinically and prognostically relevant baseline covariates, closely matched patient-level cohorts can be generated. By incorporating appropriate measures to assess covariate balance and address potential bias in comparative effectiveness study de

SUBMITTER: Nowakowski G 

PROVIDER: S-EPMC10092365 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature